News

Filter

Current filters:

Vimpat

1 to 9 of 23 results

UCB's full-year results

UCB's full-year results "confirm position of strength"

27-02-2015

The 2014 full-year financial results from Belgian drugmaker UCB “confirmed the position of strength”…

BelgiumCimziaFinancialImmunologicalsKeppraNeuproNeurologicalPharmaceuticalUCBVimpat

Daiichi Sankyo and UCB sign agreement for Vimpat in Japan

Daiichi Sankyo and UCB sign agreement for Vimpat in Japan

28-11-2014

Japanese drug major Daiichi Sankyo and Belgian drugmaker UCB have entered into an agreement to jointly…

Daiichi SankyoJapanlacosamide Tablet and InjectionLicensingNeurologicalPharmaceuticalUCBVimpat

FDA backs added use for UCB’s Vimpat

01-09-2014

Belgium’s largest drugmaker UCB said today that the US Food and Drug Administration has approved a…

NeurologicalPharmaceuticalRegulationUCBUSAVimpat

Global epilepsy market to reach $4.5 billion by 2019

Global epilepsy market to reach $4.5 billion by 2019

13-03-2014

The epilepsy therapeutics market value in the eight major countries - the USA, Canada, France, Germany,…

EisaiFycompaGlaxoSmithKlineGlobalMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpat

Actavis confirms Vimpat patent challenge and gets OK for generic Opana

15-07-2013

US generics major Actavis (NYSE: ACT) confirmed on Friday (July 12) that it has filed an Abbreviated…

ActavisEndo Health SolutionsGenericsLegalNeurologicalNorth AmericaOpana ERPatentsRegulationUCBVimpat

1 to 9 of 23 results

Back to top